Drug Discovery– tag –
-
Recent ADC Landscape Update Series, Part 3: Merck–Daiichi’s CDH6 ADC R-DXd and DLL3 ADC SHR-4849 – The Next Wave in Ovarian Cancer and SCLC
In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludot In Part 3 of this series, we focus on two “second-wave” ADC programs that have at... -
Recent ADC Landscape Update Series, Part 2: Enhertu in Early HER2-Positive Breast Cancer – What DESTINY-Breast05 and 11 Mean for Future Standards of Care
In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already tr In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-b... -
Recent ADC Landscape Update Series, Part 1: AstraZeneca’s Post-Enhertu Strategy – In-house ADCs, Radiopharma and Cell Therapy to Redefine Oncology
Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. Around 2025, oncology is entering a new phase in which antibody–... -
Oncology Drug Approval News Flash：FDA approves lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma
On December 4, 2025, the U.S. Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol Myers Squibb company), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or ref... -
Big Pharma Mega Deals in the Last Few Months Series Part 6 | A Startup-Side Playbook: Building a Company That Can Partner or Stay Independent
In the previous installments of this series, we looked at recent big pharma transactions through the lenses of oncology, obesity/metabolic disease, re In the previous installments of this series, we looked at recent big pharma transactio... -
Oncology Drug Approval News Flash：FDA grants traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory CLL/SLL after covalent BTK inhibitor therapy
On December 3, 2025, the U.S. Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic l... -
Big Pharma Mega Deals in the Last Few Months Series Part 5 | How Investors Can Read and Use Big Pharma Transactions
When investors follow big pharma transactions, it is tempting to focus on headline numbers: total deal value, takeover premium, “multi-billion” labels. When investors follow big pharma transactions, it is tempting to focus on headline nu... -
Big Pharma Mega Deals in the Last Few Months Series Part 4 | Respiratory and Infectious Disease: From COPD and Rare Lung Disorders to Seasonal Viral Threats
Alongside oncology and metabolic disease, one of the most striking clusters in recent big pharma transactions over the last few months is respiratory and infectious disease. Alongside oncology and metabolic disease, one of the most strik... -
Big Pharma Mega Deals in the Last Few Months Series Part 2 | Next-Generation Oncology: in vivo CAR-T, ADCs, Bispecifics and Oral Biologics
Among the many big pharma transactions announced in the last few months, oncology stands out as the area where activity is both dense and conceptually rich. Among the many big pharma transactions announced in the last few months, oncolog... -
Big Pharma Mega Deals in the Last Few Months Series: Landscape and Thematic Map (Part 1)
Over the last few months, the pharmaceutical and biotech industry has seen a flurry of mega deals, many of them comfortably exceeding the $1 billion m Over the last few months, the pharmaceutical and biotech industry has seen a flurry of... -
Cancer Treatment Introductory–to–Basic Series – Overview
How to Read This 8-Part Series: Seeing the Bigger Picture of Cancer Care The “Cancer Treatment Introductory–to–Basic Series” consists of eight main articles that walk through the big picture of cancer care: overall structur The “Cancer T... -
Cancer Treatment Introductory–to–Basic Series – Part 8 (Final)
Life After Treatment and Survivorship: Shaping How You Live With and Beyond Cancer From Part 1 through Part 7 of this series, we have walked through the basics of cancer treatment: overall structure, differences in “curability” among Fro... -
Oncology Drug Approval News Flash：FDA approves durvalumab (Imfinzi) plus FLOT as perioperative therapy for resectable gastric and GEJ adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by sin... -
Cancer Treatment Introductory–to–Basic Series – Part 7
Standard Treatment, Clinical Trials, and Second Opinions: Making Informed Choices In earlier parts of this series, we looked at the overall framework of cancer treatment, differences in “curability” among cancer types, and how to th In e... -
Cancer Treatment Introductory–to–Basic Series – Part 5
Cancer-Specific “Curability”: Why Some Cancers Are Harder to Treat In the previous parts of this series, we looked at the overall framework of cancer treatment and introduced the main tools – surgery, drug therapy, radiotherapy, and part... -
Cancer Treatment Introductory–to–Basic Series – Part 6
Living with Recurrence and Metastasis: Cancer as a Long-Term Journey In Part 5, we explored why some cancers are considered “more curable” or “harder to cure,” focusing on the roles of stage, biology, and overall health. In Part 5, we ex... -
Oncology Drug Approval News Flash: FDA approves perioperative pembrolizumab plus enfortumab vedotin-ejfvfor cisplatin-ineligible muscle invasive bladder cancer (MIBC)
On November 21, 2025, the U.S. FDA approved pembrolizumab (Keytruda / Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant and adjuvant therapy for adults with muscle invasive bladder cancer (MIBC) who are e... -
Cancer Treatment Introductory–to–Basic Series – Part 4
Basics of Particle Therapy (Proton and Heavy-Ion): How It Differs from X-ray Radiotherapy In Part 3, we explored the basics of X-ray–based radiotherapy, including external beam radiation, brachytherapy, and high-precision techniques such... -
Oncology Drug Approval News Flash: FDA Grants Full Approval to Tarlatamab-dlle for ES-SCLC and Accelerated Approval to Sevabertinib for HER2-Mutated NSCLC
On November 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed after platinum... -
Oncology Drug Approval News Flash: FDA Approves Selumetinib (KOSELUGO) for Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, 2025, the U.S. Food and Drug Administration (FDA) approved selumetinib (KOSELUGO, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously appro...
